FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2915744897> ?p ?o ?g. }

• W2915744897 endingPage "997" @default.
• W2915744897 startingPage "987" @default.
• W2915744897 abstract "Background Supraflex is a sirolimus-eluting stent with a biodegradable polymer coating and ultra-thin struts. We aimed to compare Supraflex with the standard of care, Xience, an everolimus-eluting stent with a durable polymer coating, regarding clinical outcomes with a randomised trial in an all-comer population. Methods We did a prospective, randomised, single-blind, multicentre study (TALENT) across 23 centres in Europe (the Netherlands, Poland, the UK, Spain, Bulgaria, Hungary, and Italy). Eligible participants were aged 18 years or older, had one or more coronary artery stenosis of 50% or greater in a native coronary artery, saphenous venous graft, or arterial bypass conduit, and had a reference vessel diameter of 2·25–4·50 mm. Patients underwent percutaneous coronary intervention in an all-comer manner. We randomly assigned patients (1:1) to implantation of either a sirolimus-eluting stent with a biodegradable polymer coating and ultra-thin struts (Supraflex) or an everolimus-eluting stent with a durable polymer coating (Xience). Randomisation was done by local investigators by use of a web-based software with random blocks according to centre. The primary endpoint was a non-inferiority comparison of a device-oriented composite endpoint—cardiac death, target-vessel myocardial infarction, or clinically indicated target lesion revascularisation—between groups at 12 months after the procedure, assessed in an intention-to-treat population. On assumption of 1-year composite endpoint prevalence of 8·3%, a margin of 4·0% was defined for non-inferiority of the Supraflex group compared with the Xience group. This trial is registered with ClinicalTrials.gov, number NCT02870140. Findings Between Oct 21, 2016, and July 3, 2017, 1435 patients with 1046 lesions were randomly assigned to Supraflex, of whom 720 received the index procedure, and 715 patients with 1030 lesions were assigned to Xience, all receiving the index procedure. At 12 months, the primary endpoint had occurred in 35 patients (4·9 %) in the Supraflex group and in 37 patients (5·3%) in the Xience group (absolute difference −0·3% [one-sided 95% upper confidence bound 1·6%], pnon-inferiority<0·0001). Definite or probable stent thrombosis prevalence, a safety indicator, was low in both groups and did not differ between them. Interpretation The Supraflex stent was non-inferior to the Xience stent for a device-oriented composite clinical endpoint at 12 months in an all-comer population. Supraflex seems a safe and effective alternative drug-eluting stent to other stents in clinical practice. Funding European Cardiovascular Research Institute. Supraflex is a sirolimus-eluting stent with a biodegradable polymer coating and ultra-thin struts. We aimed to compare Supraflex with the standard of care, Xience, an everolimus-eluting stent with a durable polymer coating, regarding clinical outcomes with a randomised trial in an all-comer population. We did a prospective, randomised, single-blind, multicentre study (TALENT) across 23 centres in Europe (the Netherlands, Poland, the UK, Spain, Bulgaria, Hungary, and Italy). Eligible participants were aged 18 years or older, had one or more coronary artery stenosis of 50% or greater in a native coronary artery, saphenous venous graft, or arterial bypass conduit, and had a reference vessel diameter of 2·25–4·50 mm. Patients underwent percutaneous coronary intervention in an all-comer manner. We randomly assigned patients (1:1) to implantation of either a sirolimus-eluting stent with a biodegradable polymer coating and ultra-thin struts (Supraflex) or an everolimus-eluting stent with a durable polymer coating (Xience). Randomisation was done by local investigators by use of a web-based software with random blocks according to centre. The primary endpoint was a non-inferiority comparison of a device-oriented composite endpoint—cardiac death, target-vessel myocardial infarction, or clinically indicated target lesion revascularisation—between groups at 12 months after the procedure, assessed in an intention-to-treat population. On assumption of 1-year composite endpoint prevalence of 8·3%, a margin of 4·0% was defined for non-inferiority of the Supraflex group compared with the Xience group. This trial is registered with ClinicalTrials.gov, number NCT02870140. Between Oct 21, 2016, and July 3, 2017, 1435 patients with 1046 lesions were randomly assigned to Supraflex, of whom 720 received the index procedure, and 715 patients with 1030 lesions were assigned to Xience, all receiving the index procedure. At 12 months, the primary endpoint had occurred in 35 patients (4·9 %) in the Supraflex group and in 37 patients (5·3%) in the Xience group (absolute difference −0·3% [one-sided 95% upper confidence bound 1·6%], pnon-inferiority<0·0001). Definite or probable stent thrombosis prevalence, a safety indicator, was low in both groups and did not differ between them. The Supraflex stent was non-inferior to the Xience stent for a device-oriented composite clinical endpoint at 12 months in an all-comer population. Supraflex seems a safe and effective alternative drug-eluting stent to other stents in clinical practice." @default.
• W2915744897 created "2019-03-02" @default.
• W2915744897 creator A5004038723 @default.
• W2915744897 creator A5004722731 @default.
• W2915744897 creator A5005598482 @default.
• W2915744897 creator A5008587276 @default.
• W2915744897 creator A5009450210 @default.
• W2915744897 creator A5026031312 @default.
• W2915744897 creator A5029245765 @default.
• W2915744897 creator A5030343009 @default.
• W2915744897 creator A5033642948 @default.
• W2915744897 creator A5035239568 @default.
• W2915744897 creator A5036968408 @default.
• W2915744897 creator A5044646526 @default.
• W2915744897 creator A5047707907 @default.
• W2915744897 creator A5047796220 @default.
• W2915744897 creator A5048845661 @default.
• W2915744897 creator A5053721496 @default.
• W2915744897 creator A5054452062 @default.
• W2915744897 creator A5063210480 @default.
• W2915744897 creator A5063247968 @default.
• W2915744897 creator A5063792624 @default.
• W2915744897 creator A5063831983 @default.
• W2915744897 creator A5066083709 @default.
• W2915744897 creator A5071944579 @default.
• W2915744897 creator A5080398218 @default.
• W2915744897 creator A5081989604 @default.
• W2915744897 creator A5083852528 @default.
• W2915744897 creator A5084533802 @default.
• W2915744897 creator A5084631056 @default.
• W2915744897 creator A5086692319 @default.
• W2915744897 creator A5088402753 @default.
• W2915744897 creator A5091436608 @default.
• W2915744897 date "2019-03-01" @default.
• W2915744897 modified "2023-10-16" @default.
• W2915744897 title "Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial" @default.
• W2915744897 cites W1409723433 @default.
• W2915744897 cites W1555546720 @default.
• W2915744897 cites W1562999866 @default.
• W2915744897 cites W1840021307 @default.
• W2915744897 cites W196677194 @default.
• W2915744897 cites W1997760014 @default.
• W2915744897 cites W2038850561 @default.
• W2915744897 cites W2061556888 @default.
• W2915744897 cites W2087150869 @default.
• W2915744897 cites W2124385743 @default.
• W2915744897 cites W2133272102 @default.
• W2915744897 cites W2144552468 @default.
• W2915744897 cites W2156613502 @default.
• W2915744897 cites W2277182661 @default.
• W2915744897 cites W2547759268 @default.
• W2915744897 cites W2697792121 @default.
• W2915744897 cites W2747702104 @default.
• W2915744897 cites W2772242654 @default.
• W2915744897 cites W2810314526 @default.
• W2915744897 cites W2889254142 @default.
• W2915744897 cites W2916912835 @default.
• W2915744897 cites W4293577771 @default.
• W2915744897 cites W584804003 @default.
• W2915744897 cites W5864417 @default.
• W2915744897 doi "https://doi.org/10.1016/s0140-6736(18)32467-x" @default.
• W2915744897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30827782" @default.
• W2915744897 hasPublicationYear "2019" @default.
• W2915744897 type Work @default.
• W2915744897 sameAs 2915744897 @default.
• W2915744897 citedByCount "64" @default.
• W2915744897 countsByYear W29157448972019 @default.
• W2915744897 countsByYear W29157448972020 @default.
• W2915744897 countsByYear W29157448972021 @default.
• W2915744897 countsByYear W29157448972022 @default.
• W2915744897 countsByYear W29157448972023 @default.
• W2915744897 crossrefType "journal-article" @default.
• W2915744897 hasAuthorship W2915744897A5004038723 @default.
• W2915744897 hasAuthorship W2915744897A5004722731 @default.
• W2915744897 hasAuthorship W2915744897A5005598482 @default.
• W2915744897 hasAuthorship W2915744897A5008587276 @default.
• W2915744897 hasAuthorship W2915744897A5009450210 @default.
• W2915744897 hasAuthorship W2915744897A5026031312 @default.
• W2915744897 hasAuthorship W2915744897A5029245765 @default.
• W2915744897 hasAuthorship W2915744897A5030343009 @default.
• W2915744897 hasAuthorship W2915744897A5033642948 @default.
• W2915744897 hasAuthorship W2915744897A5035239568 @default.
• W2915744897 hasAuthorship W2915744897A5036968408 @default.
• W2915744897 hasAuthorship W2915744897A5044646526 @default.
• W2915744897 hasAuthorship W2915744897A5047707907 @default.
• W2915744897 hasAuthorship W2915744897A5047796220 @default.
• W2915744897 hasAuthorship W2915744897A5048845661 @default.
• W2915744897 hasAuthorship W2915744897A5053721496 @default.
• W2915744897 hasAuthorship W2915744897A5054452062 @default.
• W2915744897 hasAuthorship W2915744897A5063210480 @default.
• W2915744897 hasAuthorship W2915744897A5063247968 @default.
• W2915744897 hasAuthorship W2915744897A5063792624 @default.
• W2915744897 hasAuthorship W2915744897A5063831983 @default.
• W2915744897 hasAuthorship W2915744897A5066083709 @default.
• W2915744897 hasAuthorship W2915744897A5071944579 @default.
• W2915744897 hasAuthorship W2915744897A5080398218 @default.
• W2915744897 hasAuthorship W2915744897A5081989604 @default.
• W2915744897 hasAuthorship W2915744897A5083852528 @default.

• next